Navigation Links
Using Viagra to combat malignant melanoma
Date:11/8/2011

At first it sounds like good news: The body's own immune system gets active in almost every cancer however, not necessarily for the benefit of the patient. "We distinguish between two different types of immune response," says Professor Dr. Viktor Umansky, immunologist at DKFZ and University Medical Center Mannheim. "On the one hand, cells of the immune system specifically attack tumor cells. On the other, however, almost every tumor causes in its microenvironment a chronic inflammatory immune response which suppresses the specific antitumor immunity."

In an inflammatory immune response, immune cells of a certain type migrate into the tumor environment and release characteristic immune mediators. "Our aim is to reduce the chronic inflammations and, thus, to support the immune system in actively fighting the cancer," Umansky said.

He and his team have now studied chronic inflammation as it is caused by malignant melanoma. For their research, they used genetically-modified (transgenic) mice that spontaneously develop a type of skin cancer which is very similar to human melanoma. In the tumor environment and in metastatic lymph nodes of the animals, the investigators detected inflammatory mediators such interleukin-1-β and interferon-γ. These immune mediators attract what are called myeloid-derived suppressor cells (MDSC). These immune cells are known to inhibit the immune system's most important tumor-specific fighters, the T cells.

What exactly happens when T cells get under the influence of MDSC? When the researchers exposed T cells obtained from the spleen of a healthy mouse to MDSC in the culture dish, the T cells stopped proliferating. Moreover, the T cells reduced the level of an important activating molecule. "This shows that tumor-specific T cells are actively suppressed by myeloid-derived suppressor cells," said Umansky, explaining their findings.

The melanoma mice were then given sildenafil. This substance, which is better known under its trade name, Viagra, had already been reported to improve tumor immunity in experimental animal models several times before. Of the mice that had been given the substance with their drinking water, more than twice as many were still alive after about seven weeks as of their untreated fellows. In the animals that had been treated, both the number of tumor-specific T cells and the level of activating molecules had returned to normal. This means that sildenafil successfully neutralizes the chronic inflammation in the melanoma environment and combats the immunosuppressive activity of MDSC.

"Our research approach is special because the disease takes a very similar course in mice as melanoma does in humans," Viktor Umansky said explaining the medical relevance of his findings. "Therefore, it is very well possible that sildenafil can also inhibit the immunosuppressive effects of inflammation and thus improve antitumor immunity in people with melanoma. In this way, the drug may contribute to achieving better treatment results in malignant melanoma."


'/>"/>
Contact: Dr. Sibylle Kohlstdt
s.kohlstaedt@dkfz.de
Helmholtz Association of German Research Centres
Source:Eurekalert

Related medicine news :

1. More People Landing in the ER After Abusing Muscle Relaxant: Report
2. NYUCD awarded $2.2 million NIH grant to decode genome of caries-causing bacteria
3. Using Drug for Prevention Might Help in Hard-to-Treat Hemophilia
4. Team discovers how a cancer-causing bacterium spurs cell death
5. High tech detection of breast cancer using nanoprobes and SQUID
6. Mayo Clinic study guides physicians using therapeutic cooling to treat cardiac arrest patients
7. First report of increased safety using simultaneous techniques for cardiac testing published
8. More Teen Males Using Condoms When They First Have Sex: Survey
9. Molecular depth profiling modeled using buckyballs and low-energy argon
10. Infusing chemotherapy into the liver gives extra months of disease-free life in melanoma patients
11. Bed Bug Insecticides Causing Sickness, Officials Warn
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... ... 27, 2017 , ... Much attention has been paid to the problem of ... opioid painkillers has fallen short. From 1999 until 2010, fatal overdoses from prescription pain ... overdoses in male populations.(1) , The proportion of women using illicit drugs is also ...
(Date:2/27/2017)... ... 2017 , ... Elisa Guajardo Carothers is not your typical author. She went from working as ... Now, she writes about God, when she isn’t swimming as a performing mermaid. , Her ... BS! (Before Satan),” she offers a comedic look at the dysfunctions of God’s family, before ...
(Date:2/27/2017)... ... February 27, 2017 , ... ... on laser diffraction analysis as a tool to characterize particle size distributions in ... to obtain improved results and novel scientific findings. It describes methods of optimized ...
(Date:2/27/2017)... POUGHKEEPSIE, N. Y. (PRWEB) , ... February 27, 2017 , ... ... Society ( ILADS ) has disclosed that despite scientific studies, the Center for Disease ... of chronic Lyme disease . Kenneth B. Liegner, M.D. has compiled into ...
(Date:2/27/2017)... , ... February 27, 2017 , ... ... and alcohol treatment programs in British Columbia, Canada, at https://www.sunshinecoasthealthcentre.ca/ , is ... team. The new hire, Mackenzie Alsager, showcases the Centre's commitment to innovation in ...
Breaking Medicine News(10 mins):
(Date:2/27/2017)... OCEAN VIEW, Delaware , February 27, 2017 ... (Software, Hardware, Services), By Product (Enterprise Based, Site Based), By Delivery Mode ... Research Organizations, Healthcare Providers), Industry Analysis Report, Regional Outlook (U.S., ... , Poland , Russia , ... Japan , South Korea , Taiwan ...
(Date:2/27/2017)... , Feb. 27, 2017   Royal Philips ... a global leader in health technology, today announced ... Administration (FDA) to market its ElastQ Imaging capability, ... of ultrasound systems. ElastQ Imaging enables simultaneous imaging ... is essential for the diagnosis of various liver ...
(Date:2/27/2017)... 27, 2017  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ... company focused on tissue protection, repair and regeneration, ... Co., Ltd., received a positive response from the ... design for RGN-137 to treat epidermolysis bullosa ("EB"). ... incorporates Thymosin beta 4 ("Tß4") as the active ...
Breaking Medicine Technology: